Package Insert: Information for the User
Neupro 4 mg/24 h Transdermal Patch
Neupro 6 mg/24 h Transdermal Patch
Neupro 8 mg/24 h Transdermal Patch
Rotigotine
Read this package insert carefully before starting to use the medication, as it contains important information for you.
What is Neupro
Neupro contains the active ingredient rotigotina.
It belongs to a group of medicines known as “dopamine agonists”. Dopamine is an important messenger in the brain for movement.
What is Neupro used for
Neupro is used in adults to treat the symptoms of:
Do not use Neupro if:
Remove the Neupro patch just before having an MRI or cardioversion to avoid skin burns, as the patch contains aluminum. You can put a new patch on when these tests are finished.
Do not use Neupro if you experience any of the above. If you are unsure, talk to your doctor or pharmacist first.
Consult your doctor, pharmacist, or nurse before starting to use Neupro, as:
You may experience involuntary muscle contractions that cause abnormal movements or postures, often repetitive (dystonia), abnormal postures, or lateral flexion of the back (also called pleurostotonos or Pisa syndrome). If this happens, your doctor may decide to adjust your medication.
If you experience these symptoms after starting Neupro treatment, contact your doctor.
You may lose consciousness
Neupro may cause loss of consciousness. This can happen especially when starting Neupro treatment or when increasing the dose. Inform your doctor if you lose consciousness or feel dizzy.
Changes in behavior and abnormal thoughts
Neupro may produce adverse effects that change your behavior (how you act). If your family or caregiver, or your doctor, are concerned about changes in your behavior, it may be helpful to tell a family member or caregiver that you are using this medication and have them read the leaflet.
This includes:
For more information, see ‘Changes in behavior and abnormal thoughts’ in section 4.
Children and adolescents
This medicationshould not be administeredto children under 18 years of age because its safety and efficacy in this age group are unknown.
Use of Neupro with other medications
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication. This includes over-the-counter medications and herbal remedies.
If you are being treated with Neupro and levodopa at the same time, some adverse effects may worsen. This includes seeing or hearing things that are not real (hallucinations), uncontrolled movements related to Parkinson's disease (dyskinesia), swelling in the legs and feet.
Do not take the following medications while using Neupro, as they may reduce its effect:
Consult your doctor before using Neupro if you are taking:
Your doctor will inform you if it is safe to take these medications while using Neupro.
Use of Neupro with food, drinks, and alcohol
Since rotigotine enters the bloodstream through the skin, taking food or drinks does not affect how this medication is absorbed. Consult your doctor if you can drink alcohol while using Neupro.
Pregnancy and breastfeeding
Do not use Neupro if you are pregnant. This is because the effects of rotigotine on pregnancy and the fetus are unknown.
Do not breastfeed during Neupro treatment. This is because rotigotine may pass into breast milk and affect your baby. It is also likely to reduce milk production.
If you are pregnant or breastfeeding, or think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Driving and operating machinery
Neupro may make you feel very drowsy and may cause you to fall asleep suddenly. If this happens, do not drive. In rare cases, some people have fallen asleep while driving, leading to accidents.
Do not use tools or machinery if you feel very drowsy – or perform any activity that may put you or others at risk of serious injury.
Neupro contains sodium metabisulfite (E223)
Neupro contains sodium metabisulfite (E223), a substance that rarely may cause severe allergic reactions and bronchospasm (difficulty breathing due to narrowing of the airways).
Follow exactly the administration instructions of this medication as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist.
What dose of patch to use
The dose of Neupro you need depends on your condition – see below.
Neupro is available in patches of different doses that release the medication over 24 hours. The doses are 2 mg/24 h, 4 mg/24 h, 6 mg/24 h, and 8 mg/24 h for the treatment of Parkinson's disease.
Treatment of Parkinson's Disease
Patients not taking levodopa – early stages of Parkinson's disease
Patients taking levodopa – advanced stages of Parkinson's disease
If you have to stop taking this medication, see “Stopping treatment with Neupro”in section 3.
How to use the Neupro patches
Neupro is a patch that is applied to the skin.
If you have to stop taking this medication, see“Stopping treatment with Neupro”in section 3.
How to use the Neupro patches
Neupro is a patch that is applied to the skin.
Where to put the patch Put the adhesive side of the patch on clean, dry skin in the following areas, as indicated by the gray areas in the drawing:
|
To avoid skin irritation
|
If you continue to have skin problems caused by the patch, see “Skin problems caused by the patch” in section 4 for more information.
To prevent the patch from peeling off or falling off
If the patch falls off, you should put on a new one for the rest of the day, and the next day put on a new patch at the usual time.
How to use the patch
To open the sachet, hold both sides of the sachet with your hands. | |
2. Peel the strips. | |
3. Open the sachet. | |
4. Remove the patch from the sachet. | |
5. The adhesive side of the patch is covered by a disposable transparent cover.
| |
6.
| |
7.
| |
8.
| |
9. Double the other half of the patch back and remove the rest of the disposable cover. | |
10.
This way you ensure that the patch is in contact with the skin and the edges are well attached. | |
11. Wash your hands with water and soap immediately after handling the patch. |
Using more Neupro than you should
Using higher doses of Neupro than your doctor has prescribed can cause side effects such as nausea or vomiting, low blood pressure, seeing or hearing things that are not real (hallucinations), confusion, extreme drowsiness, involuntary movements, and convulsions.
Inform your doctor or go to the hospital as soon as possible. They will tell you what to do.
Forgetting to change the patch at your usual time
In both cases, the next day, put on a new patch at the usual time. Do not use a double dose to make up for the missed doses.
Stopping treatment with Neupro
Do not stop using Neupro without first consulting your doctor. Sudden discontinuation could cause a condition called ‘neuroleptic malignant syndrome’ that could put your life at risk. The signs include: loss of muscle movement (akinesia), muscle stiffness, fever, unstable blood pressure, increased heart rate (tachycardia), confusion, decreased consciousness (for example, coma).
If your doctor tells you to stop treatment with Neupro, thedaily doseof Neupro should begradually reduced:
If you have any other questions about the use of this medication, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everyone will experience them. Inform your doctor or pharmacist if you notice any side effects.
More likely side effects at the start of treatment
You may experiencenauseaandvomitingat the start of treatment. These side effects are usually mild or moderate and do not last long. You shouldconsult your doctorif the side effects last a long time or if they concern you.
Skin problems caused by the patch
You may experience loss of consciousness
Neupro can cause loss of consciousness. This can happen especially when you start treatment with Neupro or when your dose is increased. Inform your doctor if you lose consciousness or feel dizzy.
Changes in behavior and abnormal thoughts
Inform your doctor if you notice any change in behavior, thought, or both, as indicated below.
Your doctor will tell you how to manage or reduce the symptoms.
If your family or caregiver, or your doctor, are concerned about changes in your behavior, it may be helpful to tell a family member or caregiver that you are using this medicine and to read the leaflet. Neupro can cause anxiety or an urgent need to behave in an unusual way and not be able to control the impulse, attack, or temptation to perform certain actions that may harm you or others.
These actions may include:
Neupro can cause other abnormal behaviors and thoughts, which may include:
Inform your doctor if you notice any change in your behavior, thought, or both, as indicated above.
Your doctor will tell you how to manage or reduce the symptoms.
Allergic reactions
Inform your doctor if you notice signs of an allergic reaction – which may include swelling of the face, tongue, or lips.
Side effects if using Neupro for Parkinson's disease
Inform your doctor, pharmacist, or nurse if you experience any of the following side effects:
Very common: may affect more than 1 in 10 patients
Common: may affect up to 1 in 10 patients
Uncommon: may affect up to 1 in 100 patients
Rare: may affect up to 1 in 1,000 patients
Not known:does not know how often they occur
Inform your doctor, pharmacist, or nurse if you experience any of these side effects.
Reporting side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through thenational notification system included in theAppendix V.By reporting side effects, you can contribute to providing more information about the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the label and on the carton box.
Do not store above 86°F (30°C).
What to do with used and unused patches
Composition of Neupro
The active ingredient is rotigotine.
A patch releases 4 mg of rotigotine every 24 hours. Each patch of 20 cm2contains 9.0 mg of rotigotine.
A patch releases 6 mg of rotigotine every 24 hours. Each patch of 30 cm2contains 13.5 mg of rotigotine.
A patch releases 8 mg of rotigotine every 24 hours. Each patch of 40 cm2contains 18.0 mg of rotigotine.
The other components are:
Disposable coating: Transparent polyester film coated with fluoropolymer.
Appearance of the product and contents of the package
Neupro is a transdermal patch. It is thin and has three layers. It has a square shape with rounded corners. The outer part is brown and has the imprint Neupro 4 mg/24 h, Neupro 6 mg/24 h or Neupro 8 mg/24 h.
Neupro is available in the following formats:
Carton packs containing 7, 14, 28, 30 or 84 (multi-pack containing 3 packs of 28) patches, each patch is included in an individual sachet.
Only some package sizes may be marketed.
Marketing Authorization Holder
UCB Pharma S.A.
Allée de la Recherche 60
B-1070 Brussels
Belgium
Responsible for manufacturing
UCB Pharma S.A.
Chemin du Foriest
B-1420 Braine l’Alleud
Belgium
For more information about this medicine, please contact the local representative of the marketing authorization holder:
België/Belgique/Belgien UCB Pharma SA/NV Tél/Tel: +32-(0)2 559 92 00 | Lietuva UCB Pharma Oy Finland Tel: +358-92 514 4221 (Suomija) |
Luxembourg/Luxemburg UCB Pharma SA/NV Tél/Tel: +32-(0)2 559 92 00 | |
Ceská republika UCB s.r.o. Tel: +420-221 773 411 | Magyarország UCB Magyarország Kft. Tel.: +36-(1) 391 0060 |
Danmark UCB Nordic A/S Tlf.: +45-32 46 24 00 | Malta Pharmasud Ltd. Tel: +356-21 37 64 36 |
Deutschland UCB Pharma GmbH Tel: +49-(0) 217348 48 48 | Nederland UCB Pharma B.V. Tel: +31-(0)76-573 11 40 |
Eesti UCB Pharma Oy Finland Tel: +358-92 514 4221 (Soome) | Norge UCB Nordic A/S Tlf: +45-32 46 24 00 |
Ελλ?δα UCB Α.Ε. Τηλ: +30-2109974000 | Österreich UCB Pharma GmbH Tel: + 43-(0)1291 80 00 |
España UCB Pharma S.A. Tel: +34-91 570 34 44 | Polska UCB Pharma Sp. z o.o. Tel.: +48-22 696 99 20 |
France UCB Pharma S.A. Tél: +33-(0)1 47 29 44 35 | Portugal BIAL-Portela & Cª, S.A. Tel: +351-22 986 61 00 |
Hrvatska Medis Adria d.o.o. Tel: +385-(0)1 230 34 46 | România UCB Pharma România S.R.L. Tel: +40-21 300 29 04 |
Ireland UCB (Pharma) Ireland Ltd. Tel: +353-(0)1-46 37 395 | Slovenija Medis, d.o.o. Tel: +386-1 589 69 00 |
Ísland Vistor hf. Sími: +354-535 7000 | Slovenská republika UCB s.r.o., organizacná zložka Tel: +421-(0)2 5920 2020 |
Italia UCB Pharma S.p.A. Tel: +39-02 300 791 | Suomi/Finland UCB Pharma Oy Finland Puh/Tel: +358-92 514 4221 |
Κ?προς Lifepharma (Z.A.M.) Ltd Τηλ: +357-22 05 63 00 | Suomi/Finland UCB Pharma Oy Finland Puh/Tel: +358-92 514 4221 |
Latvija UCB Pharma Oy Finland Tel: +358-92 514 4221 (Somija) |
Last review date of this leaflet:
Other sources of information
Detailed information about this medicine is available on the website of the European Medicines Agencyhttps://www.ema.europa.eu
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.